OBSN N Stock Overview
A biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ObsEva SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 1.60 |
| 52 Week High | CHF 9.65 |
| 52 Week Low | CHF 1.55 |
| Beta | 0.90 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -97.33% |
| 5 Year Change | -99.47% |
| Change since IPO | -99.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| OBSN N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how OBSN N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how OBSN N performed against the MX Market.
Price Volatility
| OBSN N volatility | |
|---|---|
| OBSN N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: OBSN N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OBSN N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 15 | Fabien de Ladonchamps | www.obseva.com |
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA Fundamentals Summary
| OBSN N fundamental statistics | |
|---|---|
| Market cap | Mex$123.16m |
| Earnings (TTM) | -Mex$500.12m |
| Revenue (TTM) | Mex$328.69m |
0.4x
P/S Ratio-0.2x
P/E RatioIs OBSN N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBSN N income statement (TTM) | |
|---|---|
| Revenue | US$19.64m |
| Cost of Revenue | US$10.71m |
| Gross Profit | US$8.93m |
| Other Expenses | US$38.81m |
| Earnings | -US$29.88m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 14, 2023
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 45.46% |
| Net Profit Margin | -152.16% |
| Debt/Equity Ratio | 32.9% |
How did OBSN N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/18 12:41 |
| End of Day Share Price | 2023/04/20 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ObsEva SA is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Edward Nash | Canaccord Genuity |